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Abstract
Background: Analyzing drop out rates and when they occur may give important information
about the patient characteristics and trial characteristics that affect the overall uptake of an
intervention.
Methods: We searched Medline and the Cochrane library from the beginning of the databases to
May 2006 for published systematic reviews that compared the effects of self-monitoring (self-
testing) or self-management (self-testing and self-dosage) of oral anticoagulation or self-monitored
blood glucose in type 2 diabetics who were not using insulin. We assessed all study withdrawals
pre-randomization and post randomization and sought information on the reasons for
discontinuation of all participants.
To measure the differential between groups in attrition we used the relative attrition (RA), which
is equivalent to relative risk but uses attrition as the outcome (i.e. attrition in intervention group/
attrition in control group). We determined the percentage drop outs for control and intervention
groups and used DerSimonian and Laird random effects models to estimate a pooled relative
attrition. L'abbe type plots created in R (version 2.0.2) were used to represent the difference in the
relative attrition among the trials with 95% confidence areas and weights derived from the random
effects model.
Results: With self-monitoring of blood glucose in type 2 diabetes, attrition ranged from 2.3% to
50.0% in the intervention groups and 0% to 40.4% in the control groups. There was no significant
difference between the intervention and control, with an overall RA of 1.18 [95% CI, 0.70–2.01].
With self-monitoring of oral anticoagulation attrition ranged from 0% to 43.2% in the intervention
groups and 0% to 21.4% in the control group. The RA was significantly greater in the intervention
group, combined RA, 6.05 [95% CI, 2.53–14.49].
Conclusion: This paper demonstrates the use of relative attrition as a new tool in systematic
review methodology which has the potential to identify patient, intervention and trial
characteristics which influences attrition in trials.
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Loss to follow up after recruitment and attrition in rand-
omized controlled trials affects the generalisability of the
conclusions. [1,2] Loss to follow up occurs when partici-
pants' information cannot be obtained for one reason or
another, whereas attrition is the exclusion or drop-out of
individuals for a particular reason after randomization to
the intervention or control group. [2] Attrition forms one
of the four predominant biases in clinical trials: selection,
performance, attrition and detection bias. Investigators
frequently exclude patients from trial analyses, most com-
monly because of ineligibility or protocol violations. Tri-
als that exclude more patients tend to be larger and
published earlier than those that do not. [2]
Analyzing drop out rates and when they occur may give
important information about the patient characteristics
and trial characteristics that affect the overall uptake of an
intervention. It is equally important to assess the inclu-
sion and exclusion criteria's impact on subsequent drop
out rates and perhaps the most significant effect is
observed by the assessment of the comparative losses
between the control and intervention groups. [1]
To analyse the impact of relative attrition on results of sys-
tematic reviews we considered self-monitoring of oral
anticoagulation and oral diabetes as the rates of attrition
in these published systematic reviews vary considerably.
On average 22% of patients assigned to self-monitoring of
oral anticoagulation were unable to complete the inter-
vention, range of 9 – 43%. [3] For type 2 diabetics receiv-
ing oral therapy, self-monitoring, withdrawals have been
reported as high as 50%. [4,5] We aimed to analyse the
drop out rates from randomized controlled trials of self
monitoring of oral anticoagulation and oral diabetes, to
examine the patient and trial characteristics that effect
attrition. In addition we aimed to analyse the relative dif-
ference between the intervention and control groups
using a measure of relative attrition.
Methods
We searched Medline and the Cochrane library from the
beginning of the databases to May 2006 for published sys-
tematic reviews that compared the effects of self-monitor-
ing (self-testing) or self-management (self-testing and
self-dosage) of oral anticoagulation or self-monitored
blood glucose in type 2 diabetics who were not using insu-
lin. MeSH terms used were "anticoagulants", "vitamin-K"
OR "coumarins" AND "consumer-participation" OR "self-
care" OR "self-administration". For diabetes terms used
were "diabetes mellitus adult-onset" OR "diabetes melli-
tus" OR "non insulin dependent" OR "diabetes mellitus
type II" OR "NIDDM" AND "self-care" OR "self-adminis-
tration" OR "blood glucose self monitoring". In addition
we used the systematic review filter "systematic". From
these reviews we obtained the full-text papers of the
included randomized controlled trials. We also repeated
the search strategies of the systematic reviews to search for
recently published randomized controlled trials in both
areas.
Data abstraction
We assessed all studies for inclusion and exclusion criteria
and for study withdrawals before randomization and post
randomization. We extracted information on disease
characteristics and the training undertaken in the inter-
vention and control groups. We extracted descriptors on
the population studied, including the number of partici-
pants who refused or were excluded from entering the
trial. We sought information on the reasons for discontin-
uation of all participants allocated to the intervention and
the control. Where data was insufficient we wrote to
authors for clarification.
Data analysis
To measure the differential between groups in attrition we
used the relative attrition (RA), which is equivalent to rel-
ative risk but uses attrition as the outcome (i.e. attrition in
intervention group/attrition in control group). A relative
attrition of one means the attrition in both the interven-
tion and control were equivalent; less than one, attrition
is less in the intervention than the control arm, and
greater than one, attrition in the intervention group was
higher. With this measure we can estimate an average RA
and detect trials with lower or higher than average RA, and
look for trial characteristics that account for this effect.
We determined the percentage drop outs for control and
intervention groups. Due to the heterogeneity in drop out
rates between trials we used the DerSimonian and Laird
random effects models to estimate a pooled relative attri-
tion for all trials using STATA (version 8.2). Data was
entered by two reviewers independently and checked.
L'abbe type plots and Forest plots created in R (version
2.0.2) were used to represent the difference in the relative
attrition among the trials with 95% confidence areas and
weights derived from the random effects model. Hetero-
geneity was examined using chi-squared and I-squared
statistics and where possible we used meta-regression to
test for the effect of trial characteristics on attrition.
Results
For self-monitoring of blood glucose in patients with type
two diabetes, we identified five [6-10] reviews, and
included eleven randomized trials (table 1), [4,5,11-19]
comprising 1,689 participants. For oral anticoagulation
we identified four reviews [3,20-22] and included 16 ran-
domized trials (table 2), [23-38] comprising 3,788 partic-
ipants.Page 2 of 12
(page number not for citation purposes)
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Table 1: Diabetes study characteristics
Source Inclusion Criteria Duration of 
study mths.
Nos. assigned to 
Intervention & (%) drop 
out
Nos. assigned to Control 
& (%) drop out
Intervention for self-monitoring 
group
Control group 
intervention
19 Wing 1986, US NIDDM, ≥ 20% above ideal weight. 
Use oral hypoglycaemic medication 
or insulin.
14 25 (8.0) 25 (12.0) Taught to make changes in diet 
and exercise if SMBG elevated.
Standard behavioural 
weight control treatment
14 Fontbonne 1989, France NIDDM, no rapidly progressing 
diabetic complications and no 
severe illness.
6 68 (17.6) 68 (20.6) All patients had pre entry visit, 
and training in SMBG.
Usual diabetic clinic care
11 Allen 1990, US NIDDM, No prior experience of 
monitoring
6 31 (12.9) 30 (10.0) Diet and exercise counselling. 
Individual instruction for SMBG
Diet and exercise 
counselling. Individual 
instruction for SMUG
13 Estey 1990, Canada NIDDM On diet or oral 
hypoglycaemic drugs.
3 30(6.7) 30 (16.7) 3 day education program (test 
and control). Inc. nurse, 
dietician, social worker and 
pharmacist.
Same 3-day education 
programme
5 Rutten 1990, Holland Treated for NIDDM for least 6 
months. Not taking insulin. Not 
under treatment for other 
conditions.
12 66 (50) 83 (12.0) Given instruction on SMBG on 
2–5 occasions. Given advice and 
therapeutic goals.
Usual General Practice 
care
15 Gallichan 1994, UK NIDDM, on oral hypoglycaemic 
agents.
6 15 (33.3) 12 (16.7) Instruction on SMBG. Instruction on SMUG
19 Muchmore 1994, US NIDDM treated with diet alone/
diet + oral sulfonylurea 
hypoglycemic agents. No use of self 
monitoring for 3 months.
7 15 (20.0) 14 (21.4) Training in SMBG from nurse 
educator individually and in 
groups
General strategies of 
diabetes control, exercise, 
recommended by ADA.
17 Miles 1997, UK Newly diagnosed NIDDM 6 68 (18) 23 (28.0) Group education, within a week 
of diagnosis. 4 education 
sessions supervised by nurse. 
Individual SMBG techniques 
checked at 1 month.
Group education, within a 
week of diagnosis. 4 
education sessions 
supervised by nurse. 
Individual SMUG technique 
checked at 1 month.
18 Schwedes 2002, 
Germany
NIDDM, BMI > 25 kg/m2. Treated 
with diet or diet in combination 
with sulfonylureas or metformin.
6 125 (9.6) 125 (12.0) Standardized counselling and 
instruction on use of SMBG
None standardised 
counselling on diet and 
lifestyle.
4 Guerci 2003, France NIDDM, no prior experience of 
monitoring and able to carry out 
self monitoring.
6 345 (47.5) 344 (40.4) Training in SMBG by GP Usual General Practice 
care
12 Davidson 2005, US NIDDM, on entering Diabetes 
Managed Care Program.
6 43 (2.3) 45 (0) Training in SMBG by specialist 
nurse
Diabetes Managed Care 
Program.
SMBG self-monitoring of blood glucose
SMUG self-monitoring of urine glucose
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Table 2: Oral anticoagulation study characteristics
Source Inclusion Criteria Duration of 
study mths.
Nos. assigned to 
Intervention & (%) 
drop out
Nos assigned to 
Control & (%) 
drop out
Intervention for self-monitoring group Control group 
intervention
38 White 1989, US Inpatients with a duration of OAT of at least 8 
weeks §
2 26 (11.5) 24 (4.2) Management by general internists ACC
29 Horstkotte 1998, 
Germany
Outpatients with the St Jude Medical 
prosthesis ‡
N/A 75 (1.3) 75 (0) INR twice a week and contact clinic by phone PCP
34 Sawicki 1999, 
Germany
Any indication for anticoagulation and life long 
treatment ‡
6 90 (14.4) 90 (7.8) 3 educational sessions. SM PCP
23 Beyth 2000, US Inpatients § 6 163 (22.1) 162 (0) 1-hour education session and contact clinic by 
phone
PCP
24 Cromheecke 2000, 
Holland
Long term OAT at least 6 months treatment ‡ 3 101 (0) 100 (0) 2-educational sessions, SM ACC
32 Kortke 2001, 
Germany
Patients after mechanical heart valve surgery ‡ 24 305 (8.9) 295 (21.4) Trained in self-monitoring 6–11 days after 
operation
PCP
35 Sidhu 2001, UK Patients after mechanical heart valve surgery ‡ 24 51 (33.3) 49 (2.0) 2-educational sessions, SM PCP
25 Fitzmaurice 2000, UK Long term OAT at least 6 months treatment ‡ 6 30 (23.3) 26 (0) 2-educational workshops, SM PCP
27 Gadisseur 2003, 
Holland
Long term OAT at least 3 months treatment ‡ 6 99 (19.2) 161 (0) 3 educational sessions. SM by telephone ACC
28 Gardiner 2004, UK Long term OAT At least 8 months ‡ 6 44 (43.2) 40 (2.5) 2-educational sessions 1 week apart ACC
31 Khan 2004, UK At least 12 months OAT with AF. Age > 65 
yrs ‡
6 44 (9.1) 41 (4.9) 2 hour education session, contact by phone ACC
36 Sunderji 2004, Canada OAT for at least 1 month ¤ 8 70 (28.6) 70 (0) 2-educational sessions, SM PCP
33 Menendez-Jandula 
2005, Spain
OAT for at least 3 months therapy ‡ 11.8 368 (21.5) 369 (2.4) 2-educational sessions, taught by nurse. SM ACC
37 Voller 2005, Germany long term OAT with non valvular AF ‡ 5 101 (19.8) 101 (0) Standard training course of 3 sessions PCP
26 Fitzmaurice 2005, UK Unselected patients in a general practice 
population
12 337 (41.5) 280 (13.2) 2-educational sessions, taught by nurse. SM PCP or ACC
30 Katz Unpublished, US Long term OAT attending anticoagulation 
clinic ‡
12 101(0) 100(0) All patients were trained by nurse, video, and 
tested with a skills and knowledge checklist 
prior to randomization
ACC
§ Coumatrack Monitor ‡ Coagucheck System ¤ Pro time Microcoagulation system ACC: Anticoagulation Clinic Care PCP: Primary Care physician managed SM: self adjusted treatment
BMC Medical Research Methodology 2007, 7:18 http://www.biomedcentral.com/1471-2288/7/18With self-monitoring of blood glucose in type 2 diabetes
(table 1), attrition ranged from 2.3% [12] to 50.0% [5] in
the intervention groups and 0% [12] to 40.4% [4] in the
control groups. There was no significant difference
between the intervention and control, with an overall RA
of 1.18 (95% CI, 0.70 -2.01), heterogeoneity chi squared
24.87 (p value = 0.006), I-squared 59.8%. (figure 1)
Two of the included studies were considered to be of high
quality [11,12] in the Welschen systematic review and two
studies [4,18] had a significant effect of SMBG on HbA1c
results. Attrition was not significantly related to study
duration. Seven trials had less than 100 participants, [11-
13,15-17,19] and one trial of 689 participants [4]
accounted for 41% of the patients studied. Study size as
well as the year of the study revealed no significant trends
Diabetes attrition L'abbe plotFigure 1
Diabetes attrition L'abbe plot.Page 5 of 12
(page number not for citation purposes)
BMC Medical Research Methodology 2007, 7:18 http://www.biomedcentral.com/1471-2288/7/18in terms of attrition. Table 3 gives the reasons for drop
outs stated by the trial author.
Two studies report a RA smaller than the lower limit of the
95% CI, equivalent to a higher than expected attrition in
the control group (figure 2). Of these two, the Estey trial
[13] control group received a standard 3-day educational
session. A comparison between those who dropped out
and those who remained in the study did not indicate any
significant differences with respect to baseline demo-
graphics. The second (Miles) study [16] invited all newly
diagnosed diabetics attending a patient education pro-
gramme, participants were randomly allocated to blood
glucose or urinary glucose.
Three studies report a RA higher than the upper limit of
the 95% CI, equivalent to higher than expected attrition in
the intervention group. In the Gallichan study [15] most
patients preferred urine testing (71%), and 33.3%
dropped out of the intervention group. The Davidson trial
[12] recruited patients in a community clinic on entering
a diabetes managed care program. Only one patient did
not return to see the nurse or dietician after randomiza-
tion. In the Rutten trial [5] set in eight general practices,
only 50% of the treatment group proved able to carry out
accurate self-monitoring. Patients under 40 and older
than 75 years of age were excluded, as were patients with
co-morbid diseases under the care of a hospital.
In the largest trial of 689 participants, [4] the attrition was
high at 47.5% relative to 40.4% in the control group RA,
1.18 (95% CI, 0.99–1.39). This is the only trial where par-
ticipants received training in SMBG by the general practi-
tioner. Of note 299 patients were not able to provide two
HbA1c measurements in a two month run in period post
randomization, and were removed from the study. The
remaining 689 patients were asked to perform at least 6
capillary assays per week (3 different days per week
including weekends). A further 303 patients dropped out
of the study, of these 240 had a reason reported for dis-
continuation: adverse event (n = 6), patient non-compli-
ance (n = 33), consent withdrawal (n = 15), patient lost to
follow up (N = 19), death (n = 4), protocol violation (n =
21), lack of information on patients (n = 92), and other
reasons as stated in the paper (n = 110).
Self-monitoring of oral anticoagulation
With self-monitoring of oral anticoagulation (table 2)
attrition ranged from 0% [24] to 43.2% [28] in the inter-
vention groups and 0% [23-25,27,29,30,36,37] to 21.4%
[32] in the control group. The RA was significantly greater
in the intervention group, combined RA 6.05 (95% CI,
2.53–14.49), heterogeneity chi squared 120.91 (p value <
0.001), I-squared 88.4%.(figure 3)
Four of the included studies were judged to be of low
quality [28,31,32,38] in the Heneghan systematic review.
Study duration ranged from two months [38] to two
years, [32,35] four trials had less than 100 participants
[25,28,31,38] and three trials [26,32,33] accounted for
51% of the patients studied. Study size as well as the year
of the study revealed no trend in terms of attrition. In
addition attrition was not significantly related to study
duration. Furthermore analysis of self-management ver-
sus self-testing only, showed no significant difference in
relative attrition (meta-regression p = 0.214). Table 4
gives the reasons for drop outs stated by the trial author.
Five trials report a RA higher than the upper limit of the
95% CI, equal to a higher than expected attrition in the
intervention group, (figure 4); in comparison, only one
(Kortke) [32] reported a RA below than the lower limit of
the 95% CI. In this trial patients were assigned to the inter-
vention directly after mechanical heart valve surgery. 90
patients were excluded from the analysis due to either
Table 3: Drop out reasons in trials of Diabetes
Source Reasons Given for drop out in the intervention and control group
19 Wing 1986, US Moved out of area, patient withdrawal and exclusion.
14 Fontbonne 1989, France Lost to follow up, no reasons given
11 Allen 1990, US Inappropriate randomization and drop outs for unknown reasons
13 Estey 1990, Canada Hospitalizations, initiation of insulin therapy, one death and failure to keep clinic appointments
5 Rutten 1990, Holland Unwilling or incapable of self-monitoring, death, referral to internist, failure to adhere to protocol, moved out of the 
area and admission to hospital
15 Gallichan 1994, UK Failure to present for re-testing
19 Muchmore 1994, US No reasons given
17 Miles 1997, UK Refusal to change over to alternative strategy, patients found the monitoring too stressful, conversion to insulin, 
moved out of area, found not to have diabetes post randomization and protocol violations
18 Schwedes 2002, Germany No reasons given
4 Guerci 2003, France Adverse events, patient non-compliance, consent withdrawal, loss to follow up, death, protocol violation, lack of 
information and other reasons
12 Davidson 2005, US Patient failed to return for follow up appointment.Page 6 of 12
(page number not for citation purposes)
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phase.
Of these five trials with higher RA one studied less than a
100 individuals: the Fitzmaurice trial [25] set in six gen-
eral practices gave patients two training sessions and
assessed competency for self-testing. Common reasons in
this trial for exclusions pre-randomization were manual
dexterity (13%), anxiety (12%), too elderly (12%), physi-
cally unwell (8%) and lack of cognitive ability (8%). Dur-
ing the study failure to attend training was the most
frequent reason for withdrawal. Three trials [23,27,37]
had similar drop outs in the intervention groups (range
19.2%–22.1%) and no drop outs in the control group.
Beyth [23] recruited and trained hospitalized patients 65
years of age or older, 31 patients refused the intervention
post randomization. Of 720 patients approached in the
Gaddiseur trial [27] – set in anticoagulation clinics – 536
refused or were ineligible or unavailable. Of these 33%
preferred existing system, 25% were too old, nervous or
uncertain and 30% had no time or were not interested.
Common reasons for drop outs were failing the training,
problems with self dosing and differences greater than
20% between laboratory measures and the self testing
device. The Voller trial [37] was discontinued due to poor
recruitment, and the group comparisons were confined to
an analysis of the INR measurements. Sunderji [36]
recruited patients from a tertiary care institution or by
referral as an outpatient. Clinical pharmacists and physi-
cians selected patients on their assessment of competence,
compliance and willingness to manage their own therapy.
Despite this selection process 29% of the intervention
group discontinued self testing compared to no drop outs
in the control group: drop out reasons included difficulty
with the monitor and a preference for physician manage-
ment.
Three trials had very low drop out rates overall. [24,29,30]
Katz unpublished trial [30] was set in anticoagulation
clinics in a large integrated health system – mean age 63
years. Pre randomization patients had to prove they could
schedule and attend anticoagulation clinics. A number
found attending the anticoagulation clinics was geograph-
ically inaccessible. Patients phoned in results and were
Diabetes attrition Forest plotFigure 2
Diabetes attrition Forest plot.Page 7 of 12
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BMC Medical Research Methodology 2007, 7:18 http://www.biomedcentral.com/1471-2288/7/18regularly contacted for telephone interviews. Horstkotte
[29] recruited 150 consecutive patients directly following
mechanical heart valve surgery. Cromheecke [24] study
was a randomized crossover between self-adjusted treat-
ment and anticoagulation clinic care.
Of the two largest trials [26,33] Menendez [33] had fewer
drop outs (21.5% vs. 41.5%). Patients received three
months of anticoagulation pre-randomization and did
not have severe medical or physical illness. Of the 368
patients randomized to self management 58 declined
before training, mostly because of a lack of confidence. Of
those who received training ten could not pass and 11
dropped out post training. The Fitzmaurice trial [26]
recruited unselected patients from general practice.
Patients had to have a long term indication for anticoagu-
Oral anticoagulation attrition L'abbe plotFigure 3
Oral anticoagulation attrition L'abbe plot.Page 8 of 12
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BMC Medical Research Methodology 2007, 7:18 http://www.biomedcentral.com/1471-2288/7/18lation and had at least six month of therapy. Of the 337
allocated to the intervention 95 did not receive it; mainly
withdrawing at the training stage. A further 45 discontin-
ued the intervention post training, the main reason being
the patients' decision. The Fitzmaurice trial was the only
paper to report the mean age of those who dropped out.
The mean age of those invited to participate was 69 years
(range 18–95) compared with a mean of 65 years for
those recruited to the study. In the intervention group the
mean age of those completing training was significantly
lower than that of those initially randomized 61 yrs v 64
yrs (p = 0.012).
Discussion
Pre-randomization drop-outs affect the external validity
of a study while post-randomization drop-out affects
internal validity, resulting in study bias. The presence of
statistical heterogeneity in the analysis of relative attrition
identifies interventions that are potentially less generalis-
able than others.
Therefore, analysis of attrition rates provides a wealth of
information over and above that of the assessment of
biasing the outcomes. For instance, RA was greater for self
monitoring of oral anticoagulation than for diabetes.
Potential reason for the increased RA for self-monitoring
oral anticoagulation include: trials being larger and of
greater duration; also many patients who self-monitored
already had experience of an alternative management
strategy and potentially preferred this system or to stay
with it in the first place. In one trial where patients went
straight on to self-monitor [32] and had no experience of
usual management drop out rates were relatively low. In
diabetes no alternative comparable testing strategy exists
apart from comparison to urine testing, when one trial
assessed patient preference, 71% preferred urine testing
over SMBG. [15] In addition control group care was not
always comparable to intervention care, for instance, con-
trol groups were often not provided training and therefore
could not fail to attend a session that the intervention
group could drop out of. Therefore additional elements of
the intervention can act to increase relative attrition.
Patients recruited to managed care programmes [12] or
integrated health systems [30] may reduce drop outs.
Individual training used in trials of anticoagulation [26]
may not fair as well as group training; peer support may
offer improved benefits over and above individual train-
ing. Possible reasons include the extra support for individ-
uals within these systems of health care. It is worth noting
for diabetes that training by general practitioners may
result in excessive drop outs. [4] In addition the require-
ment to perform many dose adjustments; may increase
Table 4: Drop out reasons in trials of Oral Anticoagulation
Source Reasons Given for drop out in the intervention and control group
38 White 1989, US Difficulty performing measurements, no reason given and changed physician
29 Horstkotte 1998, Germany No reasons given
34 Sawicki 1999, Germany Died, refused to participate, stopped warfarin therapy
23 Beyth 2000, US Physical limitations such as severe arthritis or decreased vision. Patients also preferred alternative control 
method, stopped warfarin therapy or referred to a nursing home. A number of patients also decline to 
participate
24 Cromheecke 2000, Holland Progressive visual impairment
32 Kortke 2001, Germany Difficulties with the device, travel cost to high, illness/psychological, difficulties, lack of support form physician, 
illness or death in the family, lack of interest and preference for family physician
35 Sidhu 2001, UK Patients declined training due to distance from home and lack of confidence in technique. Difficulty obtaining 
samples, preference for general practitioner management and technical problems with the instrument
25 Fitzmaurice 2000, UK Did not attend training sessions, failed training assessment, loss of confidence in self – management and problems 
with manual dexterity.
27 Gadisseur 2003, Holland Patients could not find the time for training, excluded during training and not agreeing with the randomization 
process
28 Gardiner 2004, UK Poor compliance, serious illness, failure to attend training, visual problems, poor dexterity, difficulty obtaining 
sample, moved to another area and patient death
31 Khan 2004, UK Unable to self-monitor, discontinued warfarin before study completion
36 Sunderji 2004, Canada Stopped warfarin therapy, withdrawal of consent, difficulty with device, preference for physician management 
and adverse events
33 Menendez-Jandula 2005, Spain Declined before training mainly due to lack of self confidence, unable to cope with self-management and could 
not pass training course
37 Voller 2005, Germany No reasons given
26 Fitzmaurice 2005, UK Lost to follow up with no reason, withdrew consent, withdrawn at training stage, did not attend training, adverse 
event, discontinued warfarin, moved out of the area, and death
30 Katz Unpublished, US No drop outs reported
§ Coumatrack Monitor ‡ Coagucheck System ¤ Pro time Microcoagulation system ACC: Anticoagulation Clinic Care PCP: Primary Care physician 
managed SM: self adjusted treatmentPage 9 of 12
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difficult to perform.
Reported reasons for individuals not undertaking or com-
pleting self-monitoring were poor dexterity, anxiety, too
elderly, concurrent illness and lack of cognitive ability. We
consider that age should not be a restriction to self-moni-
toring, however in the one trial [26] that used an unse-
lected population and reported the mean age of the
population attrition, drop out rates were higher, the age of
participants who successfully self-monitored was younger
than those who initially entered the trial. Whether the
major factor here was physician reluctance to continue
with self-monitoring or the patient decision cannot be
clarified by the current paper. However, where age affects
conditions such as frailty, dexterity or visual impairment
then as a co-factor it becomes a restriction to self-monitor-
ing.
Of interest some trials excluded those unable to attend the
training or set distance limits due to the control group
treatment and trial monitoring required. [33] Thus these
trials potentially excluded those most likely to benefit
from self-monitoring.
Finally, despite attempts by clinical pharmacists and phy-
sicians attempts to assess patients' competence, compli-
ance and willingness to manage their own therapy
attrition remained high [36] therefore further research
should focus on effective assessment and targeting of self-
testing.
There are limitations to the data we have presented. These
are mainly due to under reporting of the reasons for drop-
ping out of the trial from both arms. Thus we could not
test for the interaction effects. However to further this area
of research we are planning an individual patient data
meta-analysis and collecting further drop out data, in
addition to clinical outcomes.
Conclusion
In conclusion this paper demonstrates the use of relative
attrition as a new tool in systematic review methodology
which has the potential to identify patient, intervention
Oral anticoagulation attrition Forest plotFigure 4
Oral anticoagulation attrition Forest plot.Page 10 of 12
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BMC Medical Research Methodology 2007, 7:18 http://www.biomedcentral.com/1471-2288/7/18and trial characteristics which may influence attrition in
trials of self-monitoring of oral anticoagulation and dia-
betes. The method of relative attrition we present has the
potential to be applied to other systematic reviews besides
self-monitoring. It can be applied to both non-drug and
drug interventions to elicit the reasons for attrition. The
main limitation will be effective reporting of drop-outs in
randomized trials.
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